Transgene

Report Publication Announcement • Dec 17, 2018

Transgene Announces Financial Calendar for 2019

Strasbourg, France, December 17, 2018, 6:00 p.m. CET - Transgene (Euronext Paris: TNG) today announced its financial reporting dates for 2019:

March 20:	2018 Fiscal Year Results
May 13:	First Quarter 2019 Financial Results
May 22:	Annual Shareholders' Meeting
September 18:	First Half 2019 Financial Results
November 14:	Third Quarter 2019 Financial Results

Contacts

Transgene:	Media contacts:
Jean-Philippe Del/Lucie Larguier	Citigate Dewe Rogerson
+33 (0)3 88 27 11 21	David Dible/Marine Perrier/Sylvie Berrebi
investorrelations@transgene.fr	+44 (0)20 7638 9571
	transgene@citigatedewerogerson.com

About Transgene

Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical development, including TG1050 (a therapeutic vaccine for the treatment of chronic hepatitis B) and TG6002 (an oncolytic virus for the treatment of solid tumors).

With its proprietary Invir.IO™, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.

myvac™, an individualized MVA-based immunotherapy platform designed to integrate neoantigens, completes this innovative research portfolio.

Additional information about Transgene is available at www.transgene.fr. Follow us on Twitter: @TransgeneSA